Medivation Inc. will pay a hefty $410 million up front for global rights to Biomarin Pharmaceutical Inc.'s BMN-673 (talazoparib), a phase III poly ADP ribose polymerase (PARP) inhibitor intended to battle BRCA-mutated breast cancer and other malignancies.